Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial.

MLA

Schreglmann, S. R., et al. “Pyridostigmine Bromide versus Fludrocortisone in the Treatment of Orthostatic Hypotension in Parkinson’s Disease - a Randomized Controlled Trial.” European Journal of Neurology, vol. 24, no. 4, Apr. 2017, pp. 545–51. EBSCOhost, https://doi.org/10.1111/ene.13260.

APA

Schreglmann, S. R., Büchele, F., Sommerauer, M., Epprecht, L., Kägi, G., Hägele-Link, S., Götze, O., Zimmerli, L., Waldvogel, D., & Baumann, C. R. (2017). Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson’s disease - a randomized controlled trial. European Journal of Neurology, 24(4), 545–551. https://doi.org/10.1111/ene.13260

Chicago

Schreglmann, S R, F Büchele, M Sommerauer, L Epprecht, G Kägi, S Hägele-Link, O Götze, L Zimmerli, D Waldvogel, and C R Baumann. 2017. “Pyridostigmine Bromide versus Fludrocortisone in the Treatment of Orthostatic Hypotension in Parkinson’s Disease - a Randomized Controlled Trial.” European Journal of Neurology 24 (4): 545–51. doi:10.1111/ene.13260.